Abstract
Introduction
Renal anemia is a common complication of chronic kidney disease (CKD), which can result from impaired erythropoietin (EPO) production. Anemia contributes to cardiovascular complications, increased mortality, and poor quality of life for CKD patients [1, 2] . Many CKD patients may require treatment with erythropoiesis stimulating agents (ESA) to maintain stable correction of their hemoglobin (Hb) levels. Commercially-available ESA with short half-lives such as epoetin-α or epoetin-β (2~3 times per week) and darbepoetin-α (weekly) require relatively frequent injections. Recently, subcutaneous methoxy polyethylene glycolepoetin β (continuous erythropoietin receptor activator, CERA) was suggested as a oncemonthly injection due to its significantly longer elimination half-life that allows for a further extension of dosing intervals. So far, several studies have established that CERA successfully maintained target Hb after conversion from other ESA [3] [4] [5] [6] . There is also a report that CERA improved quality of life in CKD patients by reducing the frequency of ESA injections as well as conveniently managing anemia, especially in the outpatient clinic [7] .
Thrombosis is one of the side effects of ESA used to treat anemia in CKD patients. ESA affects thrombopoiesis and platelet function. Erythropoietin markedly enhances endothelial activation and platelet reactivity, which may adversely affect patients at cardiovascular risk [8] . However, there has been no study that compared levels of biomarkers related to platelet activity, endothelial function, and iron metabolism among the types of ESA used in patients with CKD.
In the OASIS (Once-monthly Administration of Subcutaneous CERA for the maIntenance of hemoglobin levels in patients with chronic renal anaemia who are not on dialysiS) study, a single arm, open-label study to assess the efficacy, safety and tolerability of CERA, we assessed whether or not Hb concentrations can be maintained when switching from ESA with shorter half-life to once monthly CERA. Simultaneously, levels of biomarkers associated with coagulation, endothelial function, and iron metabolism according to conversion from ESA with shorter half-life to CERA in pre-dialysis CKD patients were investigated.
Materials and Methods

Patients
Patients aged ≥ 18 years with a glomerular filtration rate (GFR) ≥ 10 mL/min/1.73m
2 by the Modification of Diet in Renal Disease (MDRD) equation, who were not on dialysis, were screened at 10 centers in Korea. They were required to have received treatment with ESA with shorter half-life (epoetin-α, epoetin-β, or darbepoetin-α) subcutaneously with the same dosing interval during the previous month, and have had no change in total weekly dose. They were also required to maintain Hb concentrations between 10.0 and 12.0 g/dL and show adequate iron status with serum ferritin > 100 ng/mL or transferrin saturation (TSAT) > 20% or hypochromic red cells < 10% at screening (−4 weeks).
Patients with poorly controlled hypertension, significant acute or chronic bleeding such as overt gastrointestinal bleeding within 8 weeks before screening or during the stability verification period, had a history of red blood cell transfusion during the previous 2 months, active malignancy or infection, hemolysis, folic acid or vitamin B12 deficiency, and pure red cell aplasia were excluded. Patients who had congestive heart failure (NYHA class IV), myocardial infarction, stroke, severe or unstable coronary artery disease, severe liver disease during the previous 3 months, or a history of previous CERA administration were also excluded. Ethical approval was obtained from the Institutional Review Board at each center and all participants in this study provided written informed consent.
Study Design
This study is a single-arm, open-label, multi-center study to assess Hb maintenance with oncemonthly subcutaneous CERA therapy in pre-dialysis patients with chronic renal anemia. The study design is shown in Figure 1 . Hb values were assessed during the stability verification period (−4, −2, and 0 weeks). Patients whose mean Hb values were not between 10.0 g/dL and 12.0 g/dL were withdrawn. The dosing frequency and the total weekly dose of ESA treatments prior to conversion were maintained through the stability verification period. Epoetin-α, epoetin-β, or darbepoetin-α was switched to subcutaneous oncemonthly CERA. Subcutaneous CERA (Mircera ® , Roche) was administered at week 0 to patients whose mean Hb values were between 10.0 g/dL and 12.0 g/dL.
The initial dose of CERA for each patient was based on the last dose of previously administered ESA in the week preceding the switch to CERA. Patients treated with receiving up to either darbepoetin-α 40 µg/ week or epoetin-α or epoetin-β 8,000 IU/week received CERA 120 µg/month.
CERA was administered every 4 weeks for 24 weeks, including a 16-week dose titration period, followed by an 8-week efficacy evaluation period. The dose of CERA was adjusted to maintain the target Hb range throughout the dose titration and efficacy evaluation periods (weeks 1 to 24). The target Hb range was defined as the individual patient's Hb within a range of ± 1.0 g/dL of the reference Hb concentration and between 10.0 and 12.0 g/dL. The reference Hb was taken as the mean of all Hb assessments during the stability verification period. CERA dose adjustments were performed as Table 1 .
Patients whose mean amplitude of upward Hb excursion was > 3.0 g/dL were defined as the Hb overshoot group. using an enzyme-linked immunosorbent assay (ELISA), hepcidin prohormone ELISA kit (DRG Instruments, Marburg, Germany) according to the manufacturer's instructions. This kit was based on antibodies specific for amino acids 28-47 of the pro-region of prohepcidin. A standard curve was produced prior to every measurement with the peptides supplied in the kit. All serum samples were measured in duplicate, and the average values were adopted.
Statistical Analyses
Demographic data were expressed as the mean ± standard deviation (SD) and analyzed using the student t-test and chi-square test, or Fischer's exact test, using SPSS software (SPSS version 14.0, Chicago, IL, USA). Changes in serum biomarkers between weeks 0 and 24 in the overall group and the non-overshoot group were compared with paired t-test. Changes in serum biomarkers in the overshoot group were compared with the Wilcoxon signed rank test because of the small number of patients in this group.
The efficacy of CERA was analyzed based on the per protocol (PP) subjects, whereas appropriate confirmatory analyses were conducted in the intention-to-treat (ITT) subjects. The PP subjects were defined as all patients with > 2 recorded Hb values during weeks 16-24, no missing administrations of CERA during weeks 16-24, and adequate iron status defined as mean serum ferritin ≥ 100 ng/mL and mean TSAT ≥ 20% during weeks 16-24. Statistical significance was determined as a P value less than 0.05.
Results
Study population
One hundred ninety-one patients were enrolled in this study and 187 patients received at least 1 dose of CERA. Of the 191 patients, 30 patients did not maintain adequate iron status during the study period, 15 patients dropped out before the end of the efficacy evaluation period because of withdrawal of informed consent or transfusion or concurrent illness etc., Table 2 . Baseline characteristics of per protocol subjects (n=145) Assessment Blood pressure, heart rate, Hb, and hematocrit level was assessed every 4 weeks for 24 weeks. White blood cell counts, platelet counts, mean corpuscular volume, serum creatinine, albumin, C-reactive protein (CRP), potassium, phosphate, and iron parameters (including serum iron, ferritin, transferrin or total iron-binding capacity, and transferrin saturation) were additionally assessed at weeks 8, 16, 20, and 24.
A 2 mL serum sample for biomarker research was obtained at the treatment initiation visit (week 0) and on the final study visit (week 24). The serum samples were immediately stored at or below −80 o C until use. Serum concentrations of soluble transferrin receptor (sTfR), E-selectin, P-selectin, and vascular cell adhesion molecule (VCAM) were measured using commercial enzyme immunoassay kits (R&D Systems, Minneapolis, MN) as instructed by the manufacturer. Serum prohepcidin concentrations were also determined Table 2 .
Of 145 patients, 80 (55.2%) had diabetes, 18 (12.4%) had ischemic heart disease, and 6 (4.1%) patients had cerebro-vascular disease. Angiotensin converting enzyme inhibitor alone was administered to 3 (2.1%) patients, and angiotensin II receptor blocker alone to 112 (77.2%) patients. Nine (6.2%) patients took both angiotensin converting enzyme inhibitor and angiotensin II receptor blockers. Concomitant iron agents were administered to 137 (77.2%) patients during the study period. The most common agent for iron supplement was oral ferrous sulfate in 133 (91.7%) patients followed by intravenous iron sucrose in 2 (1.5%) patients. Mean baseline serum ferritin and transferrin saturations were 245.8 ± 210.5 µg/L and 32.7 ± 12.1%, respectively. Before ESAs switching, 69 (47.6%) patients had used epoetin-α or epoetin-β and 76 (52.4%) patients had used darbepoetin-α.
Efficacy
One hundred twenty-one (83.4%) of the 145 PP subjects had Hb levels between 10.0 g/dL and 12.0 g/dL at week 0. In all patients, ESA with shorter half-life were switched to CERA 120 µg/month at week 0 because all had been treated with either less than epoetin-α or epoetin-β (n=69) 8,000 IU/week or darbepoetin-α (n=76) 40 µg/week during the stability verification period. Eighty four (57.9%) and 108 (74.5%) patients had Hb levels within the target range and between 10.0 g/dL and 12.0 g/dL, respectively, during the efficacy evaluation period (16~24 weeks). The mean Hb level of PP subjects was 11.3 ± 0.8 g/dL during the efficacy evaluation period. Mean Hb levels and doses of CERA administered at each visit are represented in Figure 2 . Hb levels were stably maintained, and the doses of CERA for maintaining target Hb levels were gradually reduced. CERA dose adjustments and the reason for the dose adjustments are shown in Table 3 . A total of 387 episodes of dose adjustments occurred. There were 35 (9.0%) episodes of dose increases and 352 (91.0%) episodes of dose decreases during the study period.
Hb overshoot occurred in 14 (9.7%) patients. There was no significant difference in the type of ESA with shorter half-life before switching and usage of iron agents between the overshoot and non-overshoot groups.
Biomarkers
Serum biomarkers in the PP subjects in each group at weeks 0 and 24 are shown in Table 4 . sTfR, E-selectin, and prohepcidin showed no significant differences before and after 
Safety
Any and serious adverse events (SAE) were presented in Table 5 . In total, 357 adverse events were reported in 141 of 191 patients (73.8%). Three adverse events in 3 patients were judged to be related to CERA; these were 1 decreased appetite, 1 headache, and 1 pruritus. All were considered to be mild in intensity. Thirty eight SAE were reported in 30 patients. The most common SAE were infections such as sepsis, pneumonia, and wound infection. Sixteen events of uncontrolled high blood pressure which increased ≥ 30% of blood pressure at baseline and needed to add antihypertensive agents were reported in 15 patients (7.9%). Two episodes of arteriovenous fistula complications and 1 episode of cerebral infarction developed in 2 (1%) and 1 patient (0.5%), respectively. Seven adverse events occurred in 5 patients (2.6%) leading to withdrawal of these patients from the study. One patient received a transfusion for surgery due to a femur neck fracture and dropped out of the study. During the study period, 10 patients initiated dialysis (6 patients had haemodialysis and 4 patients had peritoneal dialysis) because of progression of CKD to end-stage renal disease. One patient (0.5%) expired because of sepsis. There were no clinically relevant changes in the laboratory tests or vital signs during the study period.
Discussion
CERA has a prolonged half-life, which enables CKD patients to receive an ESA based on monthly visits to the outpatient nephrology clinic. Several studies have reported that conversion from ESA with shorter half-life to CERA successfully maintained a target Hb range in patients with CKD [3, 4, 6] . In this study, Hb levels were well maintained after switching from ESA with shorter half-life to CERA, as shown in previous studies. The conversion dose of CERA fell short of those suggested in the guidelines for switching from ESA with shorter half-life to CERA [3] . In this study, CERA dose adjustments were performed every 4 weeks. Decreases in the CERA dose occurred more frequently than increases, and the required dose of CERA was gradually reduced, which is consistent with previous study.
Although there is currently no standard definition of Hb overshoot, the mean amplitude of upward Hb excursions of >3 g/dL is commonly used based on clinical evidence [9] . Fishbane et al. reported that > 15% of patients who received recombinant human erythropoietin had Hb excursions ≥ 3 g/dL. In our study, we defined Hb overshoot as Hb excursions ≥ 3 g/dL and analyzed patient groups according Hb overshoot. Hb overshoot presented in 14 patients (9.7%), which is fewer than in the study by Fishbane et al. (> 15%). Ziakka et al. reported Table 5 . Adverse events that the type of ESA affected the target Hb level. The percentage of Hb levels > 12.5 g/dL was significantly greater when the patients were administered darbepoetin-α and CERA than administered epoetin-α and epoetin-β. They concluded that ESA with a longer half-life could cause more patients to overshoot the target Hb level [10] . In this study, since there was no data for the presence of overshoot before the ESA conversion, we were unable to compare the percentage of Hb overshoot between ESA with shorter half-life and CERA. Further studies may be needed to compare Hb overshoot between ESA with shorter half-life and CERA.
Erythropoietin could enhance endothelial activation and platelet reactivity, which may adversely affect patients at cardiovascular risk [8] . We measured biomarkers for endothelial and platelet reactivity to evaluate the effects of the type of erythropoietin. Soluble P-selectin, which is mostly derived from activated platelets, is used as a marker of platelet activation [11] . Increased platelet activation could promote a prothrombic effect [12] . There is much evidence that increased soluble P-selectin levels are associated with diseases such as ischemic stroke, atherosclerosis, and thromboembolic diseases [13, 14] . In our study, P-selectin was slightly increased after switching from ESA with shorter half-life to CERA in the Hb overshoot group, although the difference was not statistically significant. Considering that treatment with ESA may enhance platelet aggregation by correcting anemia in dialysis patients [15] , the changes in P-selectin in the Hb overshoot group may also be along the same lines, whereas P-selectin was significantly decreased in patients without Hb overshoot after switching from other ESAs to CERA. These data suggest that CERA may be more favorable than ESA with shorter half-life from the viewpoint of changes of platelet activation and prothrombotic probabilities.
E-selectin and VCAM are upregulated during inflammation and increase the adhesion of leukocytes to injured arterial endothelial cells, which is first step in subsequent atherosclerosis [16] . ESA increased E-selectin levels in healthy volunteers and haemodialysis patients, indicating substantial activation of endothelial cells [8, 17, 18] . Meanwhile, VCAM was variously affected by ESA. ESA treatment resulted in an increase of VCAM in healthy volunteers [8] , whereas decrease in haemodialysis patients [18] . A cross-sectional study in non-dialysis CKD patients by Patel et al. showed that ESA status did not significantly affect serum VCAM levels [19] . In this study, VCAM was significantly increased with conversion to CERA, although E-selectin was not affected by switching the type of ESA. Currently, there is no data establishing that the type of ESA affects endothelial markers. It is uncertain whether or not the elevated VCAM levels observed in our study were associated with CERA. Further study regarding the effect of CERA on the endothelial microenvironment could provide more information on the effects ESAs on endothelial biomarkers.
Prohepcidin is precursor molecule of hepcidin, known as iron-regulatory hormone [20] . Detection of the biologically active form of hepcidin might have some limitations. Some evidence indicates that prohepcidin can be used as a reliable indicator of hepcidin levels [21, 22] . We measured prohepcidin levels in our study, but found no significant changes before and after conversion to CERA, whereas other biomarkers related to iron metabolism, such as serum ferritin and transferrin saturation, showed significant changes after switching. Several results showed that prohepcidin levels were not correlated with ferritin [21, 23] . The patients in our study had very low CRP levels, therefore, it seems that other factors besides inflammation may modulate serum prohepcidin levels.
Adverse events considered by investigators to be related to treatment agent rarely occurred. Hypertension, known as the most common complication in CERA studies, occurred at lower rates in our study than in others [5] [6] [7] . Moreover, no SAE were assessed as being related to CERA.
Conclusion
Conversion from epoetin-α, epoetin-β, or darbepoetin-α to subcutaneous once-monthly CERA in pre-dialysis CKD patients can efficaciously maintain Hb concentration, and the
